Indeed, in an analysis of The Cancer Genome Atlas (TCGA) pan-cancer cohort found that patients with tumors harboring SETD2 mutations responded favorably to treatment with immune checkpoint inhibitors, raising the possibility for targeted therapies in SETD2-mutated cancers (28). The gene discussed is SETD2; the disease is cancer.